Zoetis recently marked the official opening of its new monoclonal antibodies (mAbs) expansion with a ribbon cutting ceremony at its site in Lincoln, Nebraska. The ceremony was attended by local officials, including U.S. Senator Pete Ricketts, Lincoln Mayor Gaylor Baird and key company leaders including Zoetis CEO Kristin Peck, and Nick Ashton, president of Global Manufacturing and Supply.

The new facility will enable the Lincoln manufacturing site to increase production of products that control osteoarthritis pain in dogs and cats – the company’s largest growing area of need for pet care customers. It will also be a home for future innovation and serve as a Veterinary Medicine R&D registration facility for the company as it looks to expand its portfolio with future innovations.

“We are excited to celebrate the opening of our new facility right here in Nebraska. This community is important to us as we have been welcomed to do business here for over a decade as Zoetis, delivering high quality, reliable supply of our animal health products for customers around the world,” said Chris Rasmussen, Zoetis site leader in Lincoln. “For the last 10 years, we have been able to grow our business, expand our site and bring more than 900 jobs to the site in Lincoln based on the world’s fundamental need for ways to keep animals healthy.”

The Lincoln site is a crucial manufacturing plant within the Zoetis supply network. It plays a vital role in producing biologics, biopharmaceuticals and pharmaceutical products for animals. With a workforce of nearly 950 colleagues operating 24/7, year-round, the site manufactures 1,239 finished goods, or stock keeping units (SKUs), for distribution to more than 100 countries worldwide.

“Our Zoetis Lincoln team has always demonstrated a commitment to the world’s veterinary community and livestock producers by delivering purpose-driven innovation that transforms the lives of animals from cats to cattle -- and it’s why we continue to invest in the operations and colleagues here,” said Kristin Peck, chief executive officer of Zoetis. “This new monoclonal antibody (mAbs) expansion will enable us to continue meeting the needs of our customers in one of the fastest growing areas of animal health, and our team in Lincoln will be critical to that future.”